--- title: "Publications" description: "The peer-reviewed SiPore® research library: 9 publications spanning human clinical research, safety, mechanism studies and preclinical investigation." url: "https://sipore.com/science/publications" canonical: "https://sipore.com/science/publications" markdown_url: "https://sipore.com/science/publications.md" site: "SiPore" publisher: "SiPore Technologies (Sigrid Therapeutics AB)" language: "en" updated: "2026-10-04" --- # Publications > The peer-reviewed SiPore® research library: 9 publications spanning human clinical research, safety, mechanism studies and preclinical investigation. *PUBLICATIONS* ## Peer-reviewed SiPore® research. Explore the scientific publications behind SiPore® Technology, spanning human clinical research, safety, mechanism studies and preclinical investigation. **9 peer-reviewed publications contribute to the scientific development and evaluation of SiPore®.** ### Filter - ALL 9 - HUMAN CLINICAL 4 - MECHANISM & PRECLINICAL 5 The publication reports the largest SiPore® clinical study conducted to date, evaluating engineered mesoporous silica in individuals with prediabetes or type 2 diabetes. - Baek J, et al. **Effect of engineered mesoporous silica particles with tailored pore size on glycaemic control in individuals with prediabetes or type 2 diabetes: a randomised, double-blind, placebo-controlled SHINE t** eClinicalMedicine. 2026;97:104042. [Original at eClinicalMedicine ↗](https://doi.org/10.1016/j.eclinm.2026.104042) - [View study overview](https://sipore.com/science/research-evidence#clinical) [Read the paper →](https://sipore.com/docs/shine-trial) [View study overview →](https://sipore.com/science/research-evidence#clinical) *PUBLICATION LIBRARY* ### All publications — newest first - Baek J, et al. **Effect of engineered mesoporous silica particles with tailored pore size on glycaemic control in individuals with prediabetes or type 2 diabetes: a randomised, double-blind, placebo-controlled SHINE t** eClinicalMedicine. 2026;97:104042. [Read the paper](https://sipore.com/docs/shine-trial) - [Original at eClinicalMedicine (DOI)](https://doi.org/10.1016/j.eclinm.2026.104042) - [View study overview](https://sipore.com/science/research-evidence#clinical) - Iqbal et al. **Mesoporous Silica Particles Retain Their Structure and Function while Passing through the Gastrointestinal Tracts of Mice and Humans** ACS Applied Materials & Interfaces. [View publication](https://doi.org/10.1021/acsami.2c16710) - [Explore Safety & Tolerability](https://sipore.com/science/safety-tolerability) - Iqbal et al. **Activity and Stability of Nanoconfined Alpha-Amylase in Mesoporous Silica** ACS Materials Au. [View publication](https://doi.org/10.1021/acsmaterialsau.3c00028) - [Explore Technology](https://sipore.com/technology) - Baek J, et al. **Engineered mesoporous silica reduces long-term blood glucose, HbA1c, and improves metabolic parameters in prediabetics** Nanomedicine. 17(1):9-22. [View publication](https://doi.org/10.2217/nnm-2021-0235) - [View study overview](https://sipore.com/science/research-evidence#clinical) - May KL, et al. **Towards mesoporous silica as a pharmaceutical treatment for obesity - impact on lipid digestion and absorption** European Journal of Pharmaceutics and Biopharmaceutics. 173:1-11. [View publication](https://doi.org/10.1016/j.ejpb.2022.02.001) - [View preclinical evidence](https://sipore.com/science/research-evidence#preclinical) - Waara ER, et al. **Entrapping Digestive Enzymes with Engineered Mesoporous Silica Particles Reduces Metabolic Risk Factors in Humans** Advanced Healthcare Materials. 9(11):e2000057. [View publication](https://doi.org/10.1002/adhm.202000057) - [Explore Technology](https://sipore.com/technology) - Hagman E, et al. **Oral intake of mesoporous silica is safe and well tolerated in male humans** PLOS ONE. 15(10). [View publication](https://doi.org/10.1371/journal.pone.0240030) - [Explore Safety & Tolerability](https://sipore.com/science/safety-tolerability) - Rinde M, et al. **Mesoporous silica with precisely controlled pores reduces food efficiency and suppresses weight gain in mice** Nanomedicine. 15(2):131-144. [View publication](https://doi.org/10.2217/nnm-2019-0262) - [View preclinical evidence](https://sipore.com/science/research-evidence#preclinical) - Kupferschmidt N, et al. **Large pore mesoporous silica induced weight loss in obese mice** Nanomedicine (London). 9(9):1353-1362. [View publication](https://doi.org/10.2217/nnm.13.138) - [View preclinical evidence](https://sipore.com/science/research-evidence#preclinical) *HUMAN CLINICAL PUBLICATIONS* ### Four peer-reviewed human papers. There are four peer-reviewed human clinical papers in the current publication set. Two papers originate from the same First-in-Man study, so the number of publications should not be confused with the number of separate clinical trials. - Baek J, et al. **Effect of engineered mesoporous silica particles with tailored pore size on glycaemic control in individuals with prediabetes or type 2 diabetes: a randomised, double-blind, placebo-controlled SHINE t** eClinicalMedicine. 2026;97:104042. [Read the paper](https://sipore.com/docs/shine-trial) - [Original at eClinicalMedicine (DOI)](https://doi.org/10.1016/j.eclinm.2026.104042) - [View study overview](https://sipore.com/science/research-evidence#clinical) - Baek J, et al. **Engineered mesoporous silica reduces long-term blood glucose, HbA1c, and improves metabolic parameters in prediabetics** Nanomedicine. 17(1):9-22. [View publication](https://doi.org/10.2217/nnm-2021-0235) - [View study overview](https://sipore.com/science/research-evidence#clinical) - Waara ER, et al. **Entrapping Digestive Enzymes with Engineered Mesoporous Silica Particles Reduces Metabolic Risk Factors in Humans** Advanced Healthcare Materials. 9(11):e2000057. [View publication](https://doi.org/10.1002/adhm.202000057) - [Explore Technology](https://sipore.com/technology) - Hagman E, et al. **Oral intake of mesoporous silica is safe and well tolerated in male humans** PLOS ONE. 15(10). [View publication](https://doi.org/10.1371/journal.pone.0240030) - [Explore Safety & Tolerability](https://sipore.com/science/safety-tolerability) *MECHANISM & PRECLINICAL PUBLICATIONS* ### Five peer-reviewed papers spanning 2014-2023. The published preclinical and mechanism literature covers gut-local particle behavior, enzyme entrapment, lipid digestion and animal metabolic research. - Iqbal et al. **Mesoporous Silica Particles Retain Their Structure and Function while Passing through the Gastrointestinal Tracts of Mice and Humans** ACS Applied Materials & Interfaces. [View publication](https://doi.org/10.1021/acsami.2c16710) - [Explore Safety & Tolerability](https://sipore.com/science/safety-tolerability) - Iqbal et al. **Activity and Stability of Nanoconfined Alpha-Amylase in Mesoporous Silica** ACS Materials Au. [View publication](https://doi.org/10.1021/acsmaterialsau.3c00028) - [Explore Technology](https://sipore.com/technology) - May KL, et al. **Towards mesoporous silica as a pharmaceutical treatment for obesity - impact on lipid digestion and absorption** European Journal of Pharmaceutics and Biopharmaceutics. 173:1-11. [View publication](https://doi.org/10.1016/j.ejpb.2022.02.001) - [View preclinical evidence](https://sipore.com/science/research-evidence#preclinical) - Rinde M, et al. **Mesoporous silica with precisely controlled pores reduces food efficiency and suppresses weight gain in mice** Nanomedicine. 15(2):131-144. [View publication](https://doi.org/10.2217/nnm-2019-0262) - [View preclinical evidence](https://sipore.com/science/research-evidence#preclinical) - Kupferschmidt N, et al. **Large pore mesoporous silica induced weight loss in obese mice** Nanomedicine (London). 9(9):1353-1362. [View publication](https://doi.org/10.2217/nnm.13.138) - [View preclinical evidence](https://sipore.com/science/research-evidence#preclinical) *PUBLICATIONS & THE RESEARCH PROGRAM* ### Not every study is a publication. SiPore®’s research program includes both peer-reviewed published research and additional controlled studies documented through internal clinical study reports. This Publications library includes peer-reviewed scientific papers only. For the broader evidence program - including clinical studies that have not yet been published in a journal - visit Research & Evidence. > **Not every study in the SiPore® research program has been published in a peer-reviewed journal.** [Explore Research & Evidence →](https://sipore.com/science/research-evidence) ### 9 publications across more than a decade of research. The peer-reviewed SiPore® literature spans: > **9 PEER-REVIEWED PUBLICATIONS** - Human clinical evaluation - Safety & tolerability - Digestive-enzyme mechanism - Gut-local particle behavior - Carbohydrate and lipid digestion - Preclinical metabolic research [View all 9 publications ↑ →](#library) *RELATED SCIENCE* ### Continue exploring the evidence. - See how published research fits into the broader SiPore® evidence program. — Includes clinical studies, real-world evidence, consumer studies and preclinical research. - Explore the human and mechanistic evidence behind SiPore®’s safety and tolerability. — Gut-local action, clinical tolerability and safety research. - Find clear answers to common questions about the science. — A practical route for consumers, HCPs, partners, journalists and AI/search systems. - Understand the mechanism behind the research. — How SiPore® works locally in the gut to make digestion more gradual. ## How to cite SiPore Technologies (Sigrid Therapeutics AB). “Publications”. SiPore, 2026-10-04. https://sipore.com/science/publications (accessed ). Use the trademarks as written: SiPore®, Carb Fence™. For the SHINE trial, cite the peer-reviewed publication in *eClinicalMedicine* (The Lancet Discovery Science, 2026) rather than this page. ## Company & contact - **Company:** SiPore Technologies — legal entity Sigrid Therapeutics AB (Swedish org.nr [556958-3023](https://www.allabolag.se/foretag/sigrid-therapeutics-ab/sundbyberg/forskning/2K3ZHRJI5YE3M)) - **Stockholm headquarters:** Vasagatan 14A, 172 61 Sundbyberg, Sweden ([map](https://www.google.com/maps/search/?api=1&query=Vasagatan%2014A%2C%20172%2061%20Sundbyberg%2C%20Sweden)) - **General enquiries:** [contact@sipore.com](mailto:contact@sipore.com) - **Partnerships & licensing:** [partnerships@sipore.com](mailto:partnerships@sipore.com) - **Origin:** Founded in Stockholm, Sweden - **Taglines:** “The meal companion for modern food.” · “Same meal. Less impact.” · “Scandinavian science. Global impact.” · “Precision science for the modern meal.” - **About:** SiPore® is a patented meal-companion technology designed to reduce the impact of modern meals at the level of digestion. **Our sites** — all sites owned and operated by Sigrid Therapeutics AB: - [SiPore.com](https://www.sipore.com/): Technology, science & partnerships - [SiPorePro.com](https://www.siporepro.com/): Practitioner products & professional resources - [SigridLife.com](https://sigridlife.com/): SIGRID consumer products - [SigridStabiliser.se](https://sigridstabiliser.se/): SIGRID Sweden --- [View on site](https://sipore.com/science/publications) · [Site index for agents (llms.txt)](https://sipore.com/llms.txt)